GlassScriptPhysician profile
Imitaz A Arain
NPI 1922113976
$2,954.78
in general payments reported to CMS, 2019-2025
25 companies · $335 in 2025
The $335 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,573 · 2020: $177 · 2021: $32.84 · 2022: $110 · 2023: $390 · 2024: $337 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $677.62 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $334.31 | 2019-2023 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.90 | 2019-2022 | |
| Electromed, INC. | $227.19 | 2019-2025 | Smartvest |
| Genentech USA, INC. | $222.24 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $154.78 | 2019-2025 | Zerbaxa, Keytruda |
| Insmed, INC. | $143.71 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $134.95 | 2024-2025 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $130.76 | 2019 | |
| Jazz Pharmaceuticals INC. | $126.18 | 2019-2024 | Xywav |
| Philips North America LLC | $112.83 | 2019-2025 | Patient Interface Software |
| Mylan Specialty L.P. | $79.10 | 2019-2024 | Yupelri |
| Baxter Healthcare | $53.79 | 2023 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Ceribell, INC. | $49.14 | 2024 | Pocket Eeg Device |
| Beigene USA, INC. | $49.02 | 2024 | Brukinsa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vapotherm INC | $32.84 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $26.69 | 2023 | Lumryz |
| Genzyme Corporation | $26.23 | 2024 | |
| Resmed Corp | $21.44 | 2019 | |
| Harmony Biosciences LLC | $21.22 | 2023 | Wakix |
| La Jolla Pharmaceutical Company | $19.90 | 2023 | Giapreza |
| Inogen, INC. | $18.71 | 2024 | |
| Shire North American Group INC | $15.13 | 2019 | |
| Vyera Pharmaceuticals, LLC | $14.01 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imitaz Arain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.